RE:Example of details involved in acquisition talks: like ONCY Idle Thoughts on a Wednesday Evening.
This is not easy to handicap; it is not meant to be easy.
From my lay perspective; PanCAN may be the best thing that could have happened to ONC/Y shareholders. They have a broad reach in the medical world, and exceptional guidance for pancreatic patients. Not to mention the brighter light now shining on pelareorep.
I do expect that Roche will sidle up in due course. They do not want grief from their shareholders for passing on pela. This has become a complicated situation with many open avenues, and it does take time.
Holding steady whilst acknowledging to myself there are no guarantees